The project presented by Ernest Giralt (IRB Barcelona) and Jordi Vila (ISGLOBAL) has been awarded € 260,000.
Of the 214 projects that applied for funding, 36 were selected on the basis of the evaluation of 103 scientists.
This is the third time that the IRB Barcelona researcher has received funding from “La Marató”.
La Fundació La Marató, run by TV3, announced the 36 projects awarded funding from the 2017 telethon devoted to infectious diseases. Among them is the project headed by Jordi Vila, from the Barcelona Institute for Global Health (ISGlobal), and Ernest Giralt, from the Institute for Research in Biomedicine, which seeks to design a chimeric molecule that would allow “in vivo” trials and provide a good alternative treatment for infections.
The 2017 call received applications from 214 projects, which were evaluated by 103 international experts in infectious diseases. Fifty-five scientists received the awards in a presentation ceremony held in the Auditorium of “La Academia de Ciencias Médicas y de la Salud de Cataluña y de Baleares”.
A large proportion of current antibiotics are not appropriate for treating multi-resistant pathogens. In this context, the project presented by Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins, and Jordi Vila, director of the Antimicrobial Resistance Initiative, proposes to develop a chimeric molecule to treat infections caused by multi-resistant bacteria such as A. baumannii, P. aeruginosa and K. pneumoniae multi. To this end, the project will follow two lines, which are expected to bring about a suitable alternative drug for the treatment of such infections.
The project has been awarded € 260,000 over two years.
In total, “La Fundació La Marató” Board has granted the 36 research projects of excellence funding amounting to € 8,302,384.
Of note, this is the third time that the scientist Ernest Giralt has received support from “La Marató”.
More information: La Marató